Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, will present results from its Phase 2b clinical trial of VK2809 at the 75th Liver Meeting® 2024. The study focuses on patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) or metabolic dysfunction associated steatohepatitis (MASH). The oral presentation is scheduled for November 19, 2024, at the San Diego Convention Center. The trial, titled 'Results from the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis and Fibrosis: A Randomized, Placebo-Controlled Trial,' will be presented by Dr. Rohit Loomba, Director of the NAFLD Research Center and Professor of Medicine at the University of California, San Diego.
Viking Therapeutics (NASDAQ: VKTX), un'azienda biofarmaceutica in fase clinica, presenterà i risultati del suo studio clinico di Fase 2b su VK2809 al 75° Liver Meeting® 2024. Lo studio si concentra su pazienti con steatoepatite non alcolica (NASH) confermata da biopsia o steatoepatite associata a disfunzione metabolica (MASH). La presentazione orale è programmata per il 19 novembre 2024, presso il San Diego Convention Center. Lo studio, intitolato 'Risultati dal Trial VOYAGE di 52 Settimane in Fase 2b di VK2809 in Pazienti con Steatoepatite Non Alcolica e Fibrosi Confermata da Biopsia: Uno Studio Randomizzato, Controllato con Placebo,' sarà presentato dal Dr. Rohit Loomba, Direttore del NAFLD Research Center e Professore di Medicina all'Università della California, San Diego.
Viking Therapeutics (NASDAQ: VKTX), una empresa biofarmacéutica en etapa clínica, presentará los resultados de su ensayo clínico de fase 2b de VK2809 en la 75ª reunión anual del hígado® 2024. El estudio se centra en pacientes con esteatosis hepática no alcohólica (NASH) confirmada por biopsia o esteatosis hepática asociada a disfunción metabólica (MASH). La presentación oral está programada para el 19 de noviembre de 2024, en el Centro de Convenciones de San Diego. El ensayo, titulado 'Resultados del Ensayo VOYAGE de 52 Semanas de Fase 2b de VK2809 en Pacientes con Esteatosis Hepática No Alcohólica y Fibrosis Confirmada por Biopsia: Un Ensayo Aleatorizado, Controlado con Placebo,' será presentado por el Dr. Rohit Loomba, Director del Centro de Investigación NAFLD y Profesor de Medicina en la Universidad de California, San Diego.
Viking Therapeutics (NASDAQ: VKTX)는 임상 단계의 생명공학 회사로 2024년 제75회 간 회의(Liver Meeting®)에서 VK2809의 2b상 임상 시험 결과를 발표할 예정입니다. 이 연구는 생검으로 확인된 비알콜성 지방간염(NASH) 또는 대사 기능 이상과 관련된 지방간염(MASH) 환자에 초점을 맞추고 있습니다. 구두 발표는 2024년 11월 19일 샌디에이고 컨벤션 센터에서 예정되어 있습니다. '생검으로 확인된 비알콜성 지방간염 및 섬유증 환자에서 VK2809의 52주 2b상 VOYAGE 시험 결과: 무작위 이중 맹검 확인 시험'이라는 제목의 이번 시험은 NAFLD 연구 센터 소장 및 샌디에이고 캘리포니아 대학교 의학부 교수인 Rohit Loomba 박사에 의해 발표됩니다.
Viking Therapeutics (NASDAQ: VKTX), une entreprise biopharmaceutique en phase clinique, présentera les résultats de son essai clinique de phase 2b sur VK2809 lors de la 75e réunion annuelle du foie® 2024. L'étude se concentre sur des patients présentant une stéatohépatite non alcoolique (NASH) confirmée par biopsie ou une stéatohépatite associée à une dysfonction métabolique (MASH). La présentation orale est prévue pour le 19 novembre 2024 au Centre de conventions de San Diego. L'essai, intitulé 'Résultats de l'essai VOYAGE de 52 semaines de phase 2b de VK2809 chez des patients avec stéatohépatite non alcoolique et fibrose confirmée par biopsie : un essai randomisé, contrôlé par placebo', sera présenté par le Dr Rohit Loomba, directeur du NAFLD Research Center et professeur de médecine à l'Université de Californie, San Diego.
Viking Therapeutics (NASDAQ: VKTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, wird die Ergebnisse seiner Phase-2b-Studie zu VK2809 auf dem 75. Liver Meeting® 2024 präsentieren. Die Studie konzentriert sich auf Patienten mit durch Biopsie bestätigter nicht-alkoholischer Steatohepatitis (NASH) oder metabolisch assoziierter Steatohepatitis (MASH). Die mündliche Präsentation ist für den 19. November 2024 im San Diego Convention Center geplant. Die Studie mit dem Titel 'Ergebnisse der 52-wöchigen Phase-2b VOYAGE-Studie zu VK2809 bei Patienten mit durch Biopsie bestätigter nicht-alkoholischer Steatohepatitis und Fibrose: Eine randomisierte, placebo-kontrollierte Studie' wird von Dr. Rohit Loomba, Leiter des NAFLD Research Center und Professor für Medizin an der Universität von Kalifornien, San Diego, präsentiert.
- Announcement of Phase 2b trial results for VK2809, showing progress in NASH/MASH treatment.
- Presentation at a prestigious event, the 75th Liver Meeting® 2024, could enhance visibility and credibility.
- Involvement of a renowned expert, Dr. Rohit Loomba, adds credibility to the study results.
- None.
Results to be Featured in Oral Late Breaker Presentation
Details of the oral presentation are as follows:
Title: Results from the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis and Fibrosis: A Randomized, Placebo-Controlled Trial
Presenting Author: Rohit Loomba, M.D., MHSc, Director, NAFLD Research Center and Professor of Medicine, University of
Session: Late Breaking Abstract Parallel Session 3
Date/Time: Tuesday, November 19, 2024, 11:00 – 11:10 a.m. Pacific Time
Location: San Diego Convention Center
About VK2809
VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone beta receptor (TRβ) that possesses selectivity for liver tissue, as well as the beta receptor subtype, suggesting promising therapeutic potential in a range of lipid disorders. The Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH; also referred to as metabolic dysfunction associated steatohepatitis, MASH) and fibrosis successfully achieved both the trial's primary and secondary endpoints. VK2809 also successfully achieved primary and secondary endpoints in a Phase 2a study for the treatment of patients with elevated LDL-C and non-alcoholic fatty liver disease (NAFLD). Selective activation of the thyroid hormone beta receptor in liver tissue is believed to favorably affect cholesterol and lipoprotein levels via multiple mechanisms, including increasing the expression of genes associated with lipid metabolism and clearance.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH; also referred to as metabolic dysfunction associated steatohepatitis, MASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-data-from-phase-2b-voyage-study-of-vk2809-in-patients-with-biopsy-confirmed-nashmash-at-the-75th-liver-meeting-2024-302302102.html
SOURCE Viking Therapeutics, Inc.
FAQ
What is the focus of the Phase 2b VOYAGE trial by Viking Therapeutics?
When and where will Viking Therapeutics present the Phase 2b VOYAGE trial results?
Who will present the results of the Phase 2b VOYAGE trial of VK2809?
What is VK2809 and its significance in the trial?
What is the significance of the 75th Liver Meeting® 2024 for Viking Therapeutics?
